Revenue increased by 24.5% to $424,889 for the quarter ended March 31, 2026, compared to $341,264 in the prior year period. Net income reached $846,100, or $0.00 per share, largely driven by non-cash gains from changes in the fair value of financial instruments. Research and development expenses were reduced by 55.9% to $1,309,401 as products transitioned toward commercialization. Cash and cash equivalents stood at approximately $5.4 million as of March 31, 2026. The company expects current cash resources to be sufficient to fund operations into the third quarter of 2026.